Is Goldman Sachs a Better Buy After Earnings Than Wall Street Thinks?

Goldman Sachs reported first-quarter equity underwriting revenue up 45% year over year to $535 million and advisory revenue up 89% to $1.5 billion, signaling a strong rebound in dealmaking. SpaceX plans to go public next month in what is expected to be the largest IPO ever, with Goldman as lead underwriter, while IPO filings reached 99 this year and proceeds rose 160% to $28.8 billion. Management expects investment banking activity to accelerate as the year progresses, supported by a very full pipeline and easier regulatory conditions.

Analysis

The immediate winner is not just GS’s underwriting line; it is the entire late-stage private-to-public monetization stack. A marquee mega-IPO resets animal spirits for venture funds, PE sponsors, lawyers, accountants, exchanges, and market-makers, but the second-order effect is that it can also pull forward a wave of delayed exits that have been sitting on balance sheets for 12–24 months. That matters because the incremental supply of new issue paper can widen trading volumes and underwriting fees, but it can also soak up liquidity from existing high-multiple growth names if the market tries to absorb too many headline deals at once.

The cleaner trade is that “deal activity up” is more durable for capital-light fee generators than for the banks with larger balance sheet and rate-sensitive exposure. If the pipeline really is full, the strongest operating leverage sits in advisory and equity capital markets, while the risk is a reversal in equity indices or a volatility spike that quickly freezes issuance windows. The key timing distinction is days-to-weeks for launch risk on any single IPO, but months for a true reacceleration in M&A close rates and underwriting backlog conversion.

The contrarian miss is that a monster IPO can be a signal of abundance, not scarcity: when the largest private companies finally choose to come out, it often marks the point where insiders believe public-market multiples are rich enough to sell into, not necessarily that the cycle has years left. That implies upside for GS may be real but less linear than the narrative suggests, with earnings beats front-loaded and consensus likely already embedding some normalization. The more asymmetric opportunity may be in infrastructure beneficiaries like NDAQ rather than the headline underwriter, because they gain from higher issuance and secondary turnover without as much single-deal concentration risk.

Key Decisions for Investors

• Long GS vs. XLF for 3-6 months: express a relative-value view that Goldman’s deal pipeline converts faster than the broader bank basket; target 8-12% outperformance, but trim if equity volatility rises materially.
• Add NDAQ on a 1-3 month horizon: use it as a lower-beta beneficiary of sustained issuance and higher secondary volumes; risk/reward is better than chasing the single-name underwriter into event risk.
• Sell downside protection on GS only after the IPO pricing window opens: if launch risk passes without a market wobble, monetize elevated implied vol via short-dated puts/collars for 20-30% annualized premium capture.
• Pair long GS / short regional banks over the next quarter: sustained capital markets strength should widen dispersion versus rate- and credit-sensitive lenders; beware if the Fed reprices cuts higher and the whole financials complex rerates together.
• If a mega-IPO is delayed or downsized, cut the pro-cyclical bank exposure quickly: the trade thesis depends on a functioning issuance window, and that can reverse in a matter of weeks if market breadth weakens.